Sale!

Ibrucent

$500.00 $400.00

Ibrucent (Ibrutinib) is a kinase inhibitor indicated for the treatment of patients with: Mantle Cell Lymphoma (MCL) who have received at least one prior therapy, Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) with 17p deletion, Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.

Ibrucent, Ibrutix, Ibrutinib

Ibrucent ( Ibrutinib)

 

Product Description: Ibrucent (Ibrutinib) is a kinase inhibitor indicated for the treatment of patients with: Mantle Cell Lymphoma (MCL) who have received at least one prior therapy, Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL) with 17p deletion, Waldenström’s Macroglobulinemia (WM), Marginal Zone Lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. Ibrucent is available in capsule form for oral administration. Capsules should be taken orally with a glass of water. Do not open, break, or chew the capsules.

Product Features:

Product Name : Ibrucent
Generic Name : Ibrutinib INN
Formulation : Capsule
Available Pack Size : 90’s in a bottle
Available Strength : 140 mg
Registrations : Bangladesh
Website www.ibrutix.com

 

Manufacturer: Incepta Pharmaceuticals Ltd

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.